The Effectiveness of the Nicotine Patch for Smoking Cessation: A Meta-analysis

JAMA: The Journal of the American Medical Association

Volumn 271, Issue 24, 1994, Pages 1940-1947

  Fiore, Michael C ^a   Smith, Stevens S ^a   Jorenby, Douglas E ^a   Baker, Timothy B ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NICOTINE; PLACEBO;

BEHAVIOR MODIFICATION; CIGARETTE SMOKING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DEPENDENT PERSONALITY DISORDER; DOUBLE BLIND PROCEDURE; HUMAN; META ANALYSIS; PATIENT COUNSELING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SMOKING CESSATION; TOBACCO; TRANSDERMAL DRUG ADMINISTRATION;

EID: 0028233466     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.1994.03510480064036     Document Type: Article

References (62)

1. Fiore MC, Jorenby DE, Baker TB, Kenford SL. Tobacco dependence and the nicotine patch: clinical guidelines for effective use. JAMA. 1992;268:2687-2694.
2. Palmer KJ, Buckley MM, Faulds D. Transdermal nicotine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy as an aid to smoking cessation. Drugs. 1992;44:498-529.
3. McKenna JP, Cox JL. Transdermal nicotine replacement and smoking cessation. Am Fam Phys. 1992;45: 2595-2601.
4. Orleans CT, Resch N, Noll E, et al. Use of transdermal nicotine in a state-level prescription plan for the elderly: a first look at 'real-world' patch users. JAMA. 1994;271:601-607.
5. CIBA-GEIGY Corp. Habitrol (Nicotine Transdermal Therapeutic System) Prescribing Information. Edison, NJ: CIBA-GEIGY Corp; 1992.
6. Lederle Laboratories. PROSTEP (Nicotine Transdermal System) Prescribing Information. Wayne, NJ: Lederle Laboratories; 1992.
7. Marion Merrell Dow Inc. Nicoderm (Nicotine Transdermal System) Prescribing Information. Kansas City, Mo: Marion Merrell Dow Inc; 1991.
8. Parke-Davis. Nicotrol (Nicotine Transdermal Systern) Prescribing Information. Morris Plains, NJ: Parke-Davis; 1992.
9. Glover ED. What can we expect from the nicotine transdermal patch? a theoretical/practical approach. Health Values. 1993;17:69-79.
10. Benowitz NL. Nicotine replacement therapy: what has been accomplished—can we do better? Drugs. 1993;45:157-170.
11. McAfee T. Transdermal nicotine: clarifications, side effects, and funding. JAMA. 1993;269:1939-1940.
12. Cepeda-Benito A. A meta-analytical review of the efficacy of nicotine chewing gum. J Consult Clin Psychol. 1993;61:822-830.
13. Hughes JR. Pharmacotherapy for smoking cessation: unvalidated assumptions, anomalies, and suggestions for future research. J Consult Clin Psychol. 1993;61:751-760.
14. Lam W, Sze PC, Sacks HS, Chalmers TC. Meta-analysis of randomised controlled trials of nicotine chewing-gum. Lancet. 1987;2:27-30.
15. Fiore MC, Novotny TE, Pierce JP, et al. Methods used to quit smoking in the United States: do cessation programs help? JAMA. 1990;263:2760-2765.
16. Lichtenstein E, Hollis J. Patient referral to a smoking cessation program: who follows through? J Fam Pract. 1992;34:739-744.
17. Hughes JR, Glaser M. Transdermal nicotine for smoking cessation. Health Values. 1993;17:25-31.
18. Dickersin K, Berlin JA. Meta-analysis: state-of-the-science. Epidemiol Rev. 1992;14:154-176.
19. Hedges LV, Olkin I. Statistical Methods for Meta-analysis. Orlando, Fla: Academic Press; 1985.
20. Mosteller F, Chalmers TC. Some progress and problems in meta-analysis of clinical trials. Stat Sci. 1992;7:227-236.
21. Abelin T, Buehler A, Muller P, Vesanen K, Imhof PR. Controlled trial of transdermal nicotine patch in tobacco withdrawal. Lancet. 1989;1:7-10.
22. CIBA-GEIGY Corp. FDA Application 020076 for Approval of Habitrol: Study 30-87. Edison, NJ: CIBA-GEIGY Corp; 1992.
23. Abelin T, Ehrsam R, Buhler-Reichert A, et al. Effectiveness of a transdermal nicotine system in smoking cessation studies. Methods Find Exp Clin Pharmacol. 1989;11:205-214.
24. CIBA-GEIGY Corp. FDA Application 020076 for Approval of Habitrol: Study 7-87. Edison, NJ: CIBA-GEIGY Corp; 1992.
25. Buchkremer G, Bents H, Horstmann M, Opitz K, Tolle R. Combination of behavioral smoking cessation with transdermal nicotine substitution. Addict Behav. 1989;14:229-238.
26. Buchkremer G, Bents H, Minneker E, Opitz K. Langfristige Effekte Einer Kombination von Transdermaler Nikotinzufuhr mit Verhaltenstherapie zur Raucherentwohnung [Long-term effects of smoking cessation therapy combining behavior therapy and transdermal nicotine substitution]. Nervenartz. 1988; 59:488-490.
27. Daughton DM, Heatley SA, Prendergast JJ, et al. Effect of transdermal nicotine delivery as an adjunct to low-intervention smoking cessation therapy: a randomized, placebo-controlled, double-blind study. Arch Intern Med. 1991;151:749-752.
28. Elan Pharmaceutical Research Corp. NDA 19-983 for Approval of PROSTEP: Study 88-02. Gainesville, Ga: Elan Pharmaceutical Research Corp; 1992.
29. Hurt RD, Lauger GG, Offord KP, Kottke TE, Dale LC. Nicotine-replacement therapy with use of a transdermal nicotine patch: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc. 1990;65:1529-1537.
30. Elan Pharmaceutical Research Corp. NDA 19-983 for Approval of PROSTEP: Study 90-03. Gainesville, Ga: Elan Pharmaceutical Research Corp; 1992.
31. Fiore MC, Kenford SL, Jorenby DE, Wetter DW, Smith SS, Baker TB. Two studies of the clinical effectiveness of the nicotine patch with different counseling treatments. Chest. 1994;105:524-533.
32. Hurt RD, Dale LC, Fredrickson PA, et al. Nicotine patch therapy for smoking cessation combined with physician advice and nurse follow-up: one-year outcome and percentage of nicotine replacement. JAMA. 1994;271:595-600.
33. Elan Pharmaceutical Research Corp. NDA 19-983 for Approval of PROSTEP: Study 90-01. Gainesville, Ga: Elan Pharmaceutical Research Corp; 1992.
34. Imperial Cancer Research Fund General Practice Research Group. Effectiveness of a nicotine patch in helping people stop smoking: results of a randomized trial in a general practice. BMJ. 1993;306:1304-1308.
35. Mulligan SC, Masterson JG, Devane JG, Kelly JG. Clinical and pharmacokinetic properties of a transdermal nicotine patch. Clin Pharmacol Ther. 1990;47:331-337.
36. Elan Pharmaceutical Research Corp. NDA 19-983 for Approval of PROSTEP: Study 88-01. Gainesville, Ga: Elan Pharmaceutical Research Corp; 1992.
37. Russell MAH, Stapleton JA, Feyerabend C, et al. Targeting heavy smokers in general practice: randomised controlled trial of transdermal nicotine patches. BMJ. 1993;306:1308-1312.
38. Sachs DPL, Sawe U, Leischow SJ. Effectiveness of a 16-hour transdermal nicotine patch in a medical practice setting, without intensive group counseling. Arch Intern Med. 1993;153:1881-1890.
39. Kabi Pharmacia. FDA Application 020150 for Approval of Nicotrol: Study 7. Piscataway, NJ: Kabi Pharmacia; 1992.
40. Tonnesen P, Norregaard J, Simonsen K, Sawe U. A double-blind trial of a 16-hour transdermal nicotine patch in smoking cessation. N Engl J Med. 1991;325: 311-315.
41. Kabi Pharmacia. FDA Application 020150 for Approval of Nicotrol: Study 1. Piscataway, NJ: Kabi Pharmacia; 1992.
42. Transdermal Nicotine Study Group. Transdermal nicotine for smoking cessation: six-month results from two multicenter controlled clinical trials. JAMA. 1991; 266:3133-3138.
43. Marion Merrell Dow. FDA Application 020165 for Approval of Nicoderm: Study 010:21 mg/day Dose and 0 mg/day Dose Conditions Only. Kansas City, Mo: Marion Merrell Dow; 1991.
44. Marion Merrell Dow. FDA Application 020165 for Approval of Nicoderm: Study 011:21 mg/day Dose and 0 mg/day Dose Conditions Only. Kansas City, Mo: Marion Merrell Dow; 1991.
45. Westman EC, Levin ED, Rose JE. The nicotine patch in smoking cessation: a randomized trial with telephone counseling. Arch Intern Med. 1993;153:1917-1923.
46. Foulds J, Stapleton J, Feyerabend C, Vesey C, Jarvis M, Russell MA. Effect of transdermal nicotine patches on cigarette smoking: a double-blind crossover study. Psychopharmacology (Berl). 1992;106:421-427.
47. Hartman N, Leong GB, Glynn SM, Wilkins JN, Jarvik ME. Transdermal nicotine and smoking behavior in psychiatric patients. Am J Psychiatry. 1991;148: 374-375.
48. Krumpe P, Malani N, Adler J, et al. Efficacy of transdermal nicotine administration as an adjunct for smoking cessation in heavily nicotine addicted smokers. Ann Rev Respir Dis. 1989;139:A337.
49. Meier-Lammerman E, Meyer M, Boleski PL. Combination of transdermal nicotine substitution and behavioural group therapy in smoking cessation. Eur Respir J. 1990;3(suppl 10):168S.
50. Rennard S, Daughton D, Fortmann S, et al. Transdermal nicotine enhances smoking cessation in coronary artery disease patients. Chest. 1991;100(suppl):5S.
51. Rose JE, Levin ED, Behm FM, Adivi C, Schur C. Transdermal nicotine facilitates smoking cessation. Clin Pharmacol Ther. 1990;47:323-330.
52. Report of the Surgeon General. The Health Consequences of Smoking: Nicotine Addiction. Washington, DC: US Dept of Health and Human Services; 1988. Publication CDC 88-8406.
53. Fleiss JL. Statistical Methods for Rates and Proportions. 2nd ed. New York, NY: John Wiley & Sons Inc; 1981.
54. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719-748.
55. SAS Institute Inc. SAS/STAT Users Guide, Release 6.03 Edition. Cary, NC: SAS Institute Inc; 1988.
56. Breslow NE, Day NE. Statistical Methods in Cancer Research. Lyon, France: International Agency for Research on Cancer; 1980;1.
57. Orleans CT. Treating nicotine dependence in medical settings: a stepped-care model. In: Orleans CT, Slade J, eds. Nicotine Addiction: Principles and Management. New York, NY: Oxford University Press; 1993:145-161.
58. Glynn TJ, Manley MW. How to Help Your Patients Stop Smoking: A National Cancer Institute Manual for Physicians. Washington, DC: US Dept of Health and Human Services, Public Health Service, National Institutes of Health; 1990. Publication NIH 90-3064.
59. Leventhal H, Baker TB, Brandon TH, Fleming R. Intervening and preventing cigarette smoking. In: Ney T, Gale A, eds. Smoking and Human Behavior. New York, NY: John Wiley & Sons Inc; 1989:313-336.
60. Ball JC, Ross A. The Effectiveness of Methadone Maintenance Treatment. New York, NY: Springer-Verlag; 1991.
61. Kottke TE, Battista RN, DeFriese GH, et al. Attributes of successful smoking cessation interventions in medical practice: a meta-analysis of 39 controlled trials. JAMA. 1988;259:2883-2889.
62. Hurt RD, Dale LC, Offord KP, et al. Serum nicotine and cotinine levels during nicotine-patch therapy. Clin Pharmacol Ther. 1993;54:98-106.